ClinicalTrials.gov
ClinicalTrials.gov Menu

Improving Stroke Rehabilitation: Spacing Effect and D-cycloserine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00720759
Recruitment Status : Completed
First Posted : July 23, 2008
Results First Posted : March 7, 2014
Last Update Posted : March 7, 2014
Sponsor:
Information provided by (Responsible Party):
VA Office of Research and Development

Brief Summary:
Each year 730,000 Americans experience a stroke. Forty percent are left with significant paralysis of one arm. Certain types of physical therapy, for example constraint induced movement therapy (CIMT), have been shown to be effective in improving arm function. However, for most subjects, improvement is modest. In this trial, we test two approaches that may increase the amount of improvement achieved: 1) distributing treatment over a greater amount of time; and 2) adding a drug, d-cycloserine, which theoretically enhances the molecular mechanisms of learning.

Condition or disease Intervention/treatment Phase
Stroke Drug: D-cycloserine + distributed treatment Behavioral: D-cycloserine + condensed treatment Drug: Placebo + distributed treatment Behavioral: Placebo + condensed treatment Phase 2

Detailed Description:

Each year, 730,000 Americans experience a stroke. Forty percent are left with persistent impairment of upper extremity function. Although scientifically vetted rehabilitation therapies for this impairment are starting to emerge, current treatment is generally unsatisfactory. Therapies that seek to engage neuroplastic mechanisms constitute one approach to this problem. A good example is constraint induced movement therapy (CIMT), a treatment that seeks, through extensive functional task practice, to overcome an acquired intentional predisposition to use the spared arm (learned non-use), and to improve motor function in the affected arm. CIMT has been tested in a host of trials, most recently a multicenter randomized controlled trial (RCT) - the EXCITE trial. These trials have generally demonstrated that on average, the treatment shows efficacy, and the results from the RCT indicate that it is more efficacious than "standard" therapies. However, problems with CIMT can be readily identified that pose research challenges: 1) on average, efficacy is limited; 2) only a fraction of subjects show substantial benefit. We propose to address these two problems in a pilot RCT of 20 subjects that will test two modifications of standard CIMT: 1) addition of a drug, d-cycloserine, that may enhance neuroplasticity by potentiating NMDA-glutamate receptor-mediated learning mechanisms; 2) delivery of a fixed amount of CIMT over a greater number of days, which according to learning research, may enhance long-term retention of gains.

All subjects in this trial will receive CIMT. Subjects will be randomized to one of 4 groups:

A. CIMT + d-cycloserine, more condensed treatment B. CIMT + d-cycloserine, less condensed treatment C. CIMT + placebo, more condensed treatment D. CIMT + placebo, less condensed treatment The primary outcome measure will be performance on the Wolf Motor Function Test (time) 3 months after completion of treatment.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Improving Stroke Rehabilitation: Spacing Effect and D-cycloserine
Study Start Date : July 2009
Actual Primary Completion Date : November 2011
Actual Study Completion Date : November 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Cycloserine
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Arm 1
D-cycloserine + distributed treatment
Drug: D-cycloserine + distributed treatment
Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
Other Name: spaced training
Sham Comparator: Arm 2
D-cycloserine + condensed treatment
Behavioral: D-cycloserine + condensed treatment
Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
Placebo Comparator: Arm 3
Placebo + distributed treatment
Drug: Placebo + distributed treatment
Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with placebo administered before each treatment session
Other Name: spaced training
Placebo Comparator: Arm 4
Placebo + condensed treatment
Behavioral: Placebo + condensed treatment
Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with placebo administered before each treatment session



Primary Outcome Measures :
  1. Wolf Motor Function Test (Time) [ Time Frame: 3 months after completion of treatment ]
    The Wolf Motor Function Test (time) score is the average time in seconds taken to perform each of 15 functional tasks ranging in difficulty from putting one's forearm on a table to stacking checkers. Participants are given 120 seconds to perform a task and if they fail, they are scored 120 for that task. Score range on the WMFT-T is 0-120, lower scores being better.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 21-80,
  • of either sex,
  • diverse ethnic background,
  • s/p a single unilateral hemispheric stroke 6 or more months prior,
  • who meet upper extremity functional criteria for participation in constraint induced movement therapy.

Exclusion Criteria:

  • History of more than minor head trauma,
  • subarachnoid hemorrhage,
  • dementia or other neurodegenerative disease,
  • multiple sclerosis,
  • lobar intracerebral hemorrhage,
  • epilepsy,
  • drug or alcohol abuse,
  • serious medical illness,
  • serum creatinine >1.5,
  • schizophrenia,
  • major refractory depression,
  • insufficient cardiopulmonary function to participate in low-intensity,
  • sustained upper extremity exercise,
  • severe visual impairment,
  • pregnancy,
  • inability to understand the potential risks and benefits of the study,
  • personally provide informed consent, and
  • understand and cooperate with treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00720759


Locations
United States, Florida
North Florida/South Georgia Veterans Health System, Gainesville, FL
Gainesville, Florida, United States, 32608
Sponsors and Collaborators
VA Office of Research and Development
Investigators
Principal Investigator: Stephen E Nadeau, MD BS BS North Florida/South Georgia Veterans Health System, Gainesville, FL

Responsible Party: VA Office of Research and Development
ClinicalTrials.gov Identifier: NCT00720759     History of Changes
Other Study ID Numbers: B6346-R
First Posted: July 23, 2008    Key Record Dates
Results First Posted: March 7, 2014
Last Update Posted: March 7, 2014
Last Verified: January 2014

Keywords provided by VA Office of Research and Development:
stroke
hemiparesis
randomized controlled trial
d-cycloserine
distributed practice
constraint induced movement therapy

Additional relevant MeSH terms:
Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Cycloserine
Anti-Infective Agents, Urinary
Anti-Infective Agents
Renal Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action